canakinumab
novartis
['nsclc', 'canakinumab', 'canopy-a', 'sclc']
 canopy-a: ph iii of adjuvant canakinumab (can) in pts with resected nsclc no evidence of benefit for can in adjuvant setting #esmo2022 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18 #SE15